Board Members and Advisors
Brent Eck, Board of Director
Brent Eck currently serves as President and Chief Executive Officer at Metagenics. Brent has over 15 years of domestic and international sales, marketing and general management experience. Prior to Metagenics, Brent held multiple senior leadership roles at Fresenius Kabi including; Executive Vice President, Executive Vice President North America, Executive Vice President Northern Europe, North America. Brent received his BS degree in Mathematics and Computer Science from Loyola University.
Michael Higgins, Chief Executive Officer
Michael Higgins has served as a member of the Kindex Board of Directors since February, 2015. Michael brings more than 25 years of experience in the Biopharmaceutical industry working with large multi-national organizations and small entrepreneurial firms. He has held leadership roles in Finance, Operations and Business Development. Mr. Higgins is currently an Entrepreneur-in-residence at Polaris Venture Partners. Prior to joining Kindex, Michael served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals from 2003 through 2014. Prior to his work at Ironwood, Mr. Higgins spent seven years at Genzyme Corporation in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development. Michael aslos served as Chief Financial Officer of Procept, Inc. Michael earned his Bachelor of Science degree from Cornell University and holds a Masters in Business Administration from the Amos Tuck School of Business at Dartmouth College.
Paul Schimmel, Ph.D.
Dr. Schimmel is the Ernest and Jean Hahn Professor at the Skaggs Institute for Chemical Biology at the Scripps Research Institute. He was previously a Professor of Biochemistry and Biophysics in the Department of Biology at MIT. Dr. Schimmel is co-author of more than 450 publications and a textbook on biophysical chemistry, is the holder of several patents and is a member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society, and the Institute of Medicine. Dr. Schimmel is a co-founder or co-founding director of several biotechnology companies, including Alkermes, Alnylam Pharmaceuticals, Sirtris Pharmaceuticals, Cubist Pharmaceuticals, Momenta Pharmaceuticals and Repligen.
Dennis A. Ausiello, MD
Denny is the Director, Center for Assessment Technology and Continuous Health (CATCH). He was physician-in-Chief, Emeritus at Massachusetts General Hospital and Chief of Medicine at Massachusetts General Hospital from 1996 until April 2013. Denny is the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School, and served as President of the Association of American Physicians in 2006. He is also a member of the Institute of Medicine of the National Academies of Science and a Fellow of the American Academy of Arts and Sciences. Denny serves as a Director of Alnylam Pharmaceuticals, TARIS BioMedical, Inc. and several non-profit organizations. Denny is also a member of the Pfizer Board of Directors, and the scientific advisory boards of Bind Therapeutics and Blend Therapeutics.
Jeffrey Bland, Ph.D., FACN, FACB
Dr. Bland is an internationally recognized leader in the nutritional medicine field and Co-Founder of Kindex Pharmaceuticals. He is currently also Founder and President of the not-for-profit Personalized Lifestyle Medicine Institute. He previously served as President and CSO of Metagenics and was the founder and CEO of Healthcomm International. Dr. Bland began his career as a Professor of Biochemistry at the University of Puget Sound and as a Director of Nutritional Research at the Linus Pauling Institute of Science and Medicine.
Jeff is a Managing Principal of Avistone, a real estate investment management firm and Co-Founder of Kindex Pharmaceuticals. He was the founder and CEO of Metagenics Inc., a nutrigenomics and lifestyle medicine company, from 1983 to 2010. Under Jeffrey’s leadership, the company, which began operations in Southern California 30 years ago, grew to an international presence with manufacturing and/or distribution facilities located in 46 counties, employing over 1,000, offering over 1,200 products to more than 75,000 healthcare providers. During his tenure as CEO of Metagenics, Jeffrey received numerous honors and awards, including the “Family Business of the Year” award by Chapman College, winner of “Equity Deal of the Year” award by Orange County Institute for Corporate Development, and was nominated for Entrepreneur of the Year in Orange County California by Ernst & Young. In 2009, Jeffrey negotiated the sale of Metagenics.